title: Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study.
abstract: Dose proportionality in some pharmacokinetic parameters for thioridazine and its two active metabolites (mesoridazine and sulforidazine) was investigated in 11 healthy human subjects following oral administration of three single doses (25, 50, and 100 mg) of thioridazine hydrochloride separated in each case by an interval of two weeks. Also, after a further two weeks, another 100-mg dose of thioridazine (divided as 5 mg every 0.5 h) was administered to all the volunteers to investigate the effect of a slow rate of dosage input on the pharmacokinetic parameters of this drug. An HPLC method was used to measure concentrations of thioridazine, mesoridazine, and sulforidazine in plasma samples collected up to 72 h following each dose. Dose proportionality for the three single doses of thioridazine was observed for all three analytes in the area under the plasma concentration versus time curves (AUC infinity 0 or AUCt0) and the maximum plasma concentration (Cmax) in that the relationships between the dose and these parameters were each describable by an equation for a straight line (r2 greater than or equal to 0.8). However, the mean apparent distribution and elimination rate constants for thioridazine and mesoridazine and the mean apparent oral clearance for thioridazine decreased significantly with increasing dose. This suggests nonlinear trends in the elimination kinetics at high doses of thioridazine. When a 100-mg divided oral dose of thioridazine was administered, no statistically significant differences between single and divided doses were observed in the mean AUC infinity 0 or AUCt0 for thioridazine or sulforidazine. A significant decrease in the mean AUC infinity 0 or AUCt0 was observed for mesoridazine after the administration of the divided dose.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: College of Pharmacy, University of Saskatchewan, Saskatoon, Canada.
authors.forename: B S
authors.initials: BS
authors.lastname: Chakraborty
authors.forename: K K
authors.initials: KK
authors.lastname: Midha
authors.forename: G
authors.initials: G
authors.lastname: McKay
authors.forename: E M
authors.initials: EM
authors.lastname: Hawes
authors.forename: J W
authors.initials: JW
authors.lastname: Hubbard
authors.forename: E D
authors.initials: ED
authors.lastname: Korchinski
authors.forename: M G
authors.initials: MG
authors.lastname: Choc
authors.forename: W T
authors.initials: WT
authors.lastname: Robinson
mesh_terms: D000328:Adult; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D008297:Male; D008653:Mesoridazine / Q000097:blood; D010640:Phenothiazines / Q000097:blood; D013881:Thioridazine / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics*
chemical_list: D010640:Phenothiazines; D008653:Mesoridazine; C040634:sulforidazine; D013881:Thioridazine